Dimerix Ltd has released a press release.
Dimerix Receives A$6.0M R&D Tax Incentive Rebate
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Dimerix
- Appendix 4E and 2022 Annual Report
- CLARITY 2.0 COVID-19 Study Concludes Recruitment
- New Patent Family Application for DMX-700
- DMX-700 Study Shows Significant 80% Reduction in Lung Injury
- REMAP-CAP COVID-19 Study Analysis Update
Later from Dimerix
- Chair address and CEO presentation to AGM
- CLARITY 2.0 COVID-19 Study Outcome
- DMX-200 FSGS Phase 3 Trial Part 1 Recruitment Achieved
- FDA Confirms Inclusion of Paediatrics in ACTION3 Study
- Successful Completion of DSMB Review of Phase 3 FSGS Trial
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix